This corrects advice issued on 26 February when it was stated that the share capital comprised 13,696,384 ordinary shares.

Ivy Medical Chemicals' principal activity is in the development of a patented combination product called CV247.

CV247 has been the subject of a series of studies in companion animals and human patients to assess its potential as a possible treatment for various cancers and its positive effect on quality of life.

In animals, CV247 has been studied in several trials in mice and two studies in dogs in the UK have been undertaken.

Story provided by Business Financial Newswire